microRNA-21 Governs TORC1 Activation in Renal Cancer Cell Proliferation and Invasion
暂无分享,去创建一个
Falguni Das | Goutam Ghosh Choudhury | Hanna E. Abboud | D. Parekh | H. Abboud | K. Block | F. Das | B. Kasinath | G. G. Choudhury | C. Mandal | Nirmalya Dey | Chandi Charan Mandal | Nandini Ghosh-Choudhury | Dipen J. Parekh | Karen Block | Balakuntalam S. Kasinath | Nirmalya Dey | N. Ghosh‐Choudhury | N. Ghosh-choudhury
[1] S. Signoretti,et al. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma , 2010, Clinical Cancer Research.
[2] M. Michael,et al. The VHL-dependent regulation of microRNAs in renal cancer , 2010, BMC medicine.
[3] J. Avruch,et al. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.
[4] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[5] F. Monzon,et al. Molecular Classification of Adult Renal Epithelial Neoplasms Using MicroRNA Expression and Virtual Karyotyping , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[6] Tushar Patel,et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.
[7] Anna M. Krichevsky,et al. miR-21: a small multi-faceted RNA , 2008, Journal of cellular and molecular medicine.
[8] E. Abraham,et al. Identification of a microRNA signature in renal fibrosis: role of miR-21. , 2011, American journal of physiology. Renal physiology.
[9] Bin Tean Teh,et al. MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.
[10] Kenneth M. Yamada,et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. , 1998, Science.
[11] A. Hinnebusch,et al. Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets , 2009, Cell.
[12] S. Signoretti,et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.
[13] F. Das,et al. Mesangial Cell Hypertrophy by High Glucose Is Mediated by Downregulation of the Tumor Suppressor PTEN , 2006, Diabetes.
[14] A. Hata,et al. SMAD proteins control DROSHA-mediated microRNA maturation , 2008, Nature.
[15] Norbert Hollaender,et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.
[16] Falguni Das,et al. MicroRNA-21 Orchestrates High Glucose-induced Signals to TOR Complex 1, Resulting in Renal Cell Pathology in Diabetes* , 2011, The Journal of Biological Chemistry.
[17] F. Luan,et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. , 2003, Kidney international.
[18] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[19] W. Kaelin. Treatment of kidney cancer , 2009, Cancer.
[20] K. Ghoshal,et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.
[21] Shunyou Wang,et al. PTENless means more. , 2004, Developmental biology.
[22] L. Skoog,et al. PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer , 2007, Clinical Cancer Research.
[23] P. Tamboli,et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases , 2011, Cancer.
[24] A. Hata,et al. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. , 2010, Molecular cell.
[25] M. Loda,et al. Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation , 2010, Science Signaling.
[26] S. Saal,et al. MicroRNAs and the kidney: coming of age , 2009, Current opinion in nephrology and hypertension.
[27] Nobuyuki Shishido,et al. Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.
[28] A. López-Guillermo,et al. MicroRNA expression profiling in classic Hodgkin lymphoma. , 2008, Blood.
[29] Shuomin Zhu,et al. miR-21-mediated tumor growth , 2007, Oncogene.
[30] M. Hall,et al. Activation of mTORC 2 by Association with the Ribosome , 2011 .
[31] W. Kaelin. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.
[32] J. Iacomini,et al. Identification of a microRNA signature of renal ischemia reperfusion injury , 2010, Proceedings of the National Academy of Sciences.
[33] M. Milowsky,et al. Chemotherapeutic strategies for renal cell carcinoma. , 2003, The Urologic clinics of North America.
[34] Paul J. Williams,et al. NAD(P)H Oxidases Regulate HIF-2α Protein Expression* , 2007, Journal of Biological Chemistry.
[35] J. Herman,et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.
[36] T. Yoneda,et al. Simvastatin Prevents Skeletal Metastasis of Breast Cancer by an Antagonistic Interplay between p53 and CD44* , 2011, The Journal of Biological Chemistry.
[37] Margaret S. Ebert,et al. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.
[38] H. Gómez,et al. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer , 2010, Cancer and Metastasis Reviews.
[39] J. Blenis,et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.
[40] T. Maeda,et al. Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin* , 2008, Journal of Biological Chemistry.
[41] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[42] H. Abboud,et al. TSC2 Deficiency Increases PTEN via HIF1α* , 2009, The Journal of Biological Chemistry.
[43] Lin He. Posttranscriptional Regulation of PTEN Dosage by Noncoding RNAs , 2010, Science Signaling.
[44] Lewis C Cantley,et al. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. , 2005, Genes & development.
[45] Hongyu Zhou,et al. mTOR signaling in cancer cell motility and tumor metastasis. , 2010, Critical reviews in eukaryotic gene expression.
[46] H. Abboud,et al. Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[47] Tomohiko Maehama,et al. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.
[48] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[49] E. Olson,et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. , 2010, Cancer cell.
[50] Y Dai,et al. Microarray analysis of microRNA expression in renal clear cell carcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[51] P. A. van den Brandt,et al. Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis , 2008, Clinical Cancer Research.
[52] Jennifer Couzin,et al. MicroRNAs Make Big Impression in Disease After Disease , 2008, Science.
[53] Xinjiang Wang,et al. Post-translational regulation of PTEN , 2008, Oncogene.
[54] A. Dominiczak,et al. miR-21 and miR-214 are consistently modulated during renal injury in rodent models. , 2011, The American journal of pathology.
[55] J. Crespo,et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.
[56] Shile Huang,et al. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins , 2008, Oncogene.
[57] T. Hunter,et al. Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.
[58] C. Mandal,et al. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. , 2010, Cellular signalling.
[59] E. Hafen,et al. Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB , 2002, Science.
[60] Dianqing Wu,et al. Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate* , 2011, The Journal of Biological Chemistry.
[61] J. Blenis,et al. Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb , 2003, Current Biology.
[62] Cornelis J. Weijer,et al. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN , 2009, Oncogene.
[63] G. Bhanot,et al. Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.
[64] Marty W. Mayo,et al. Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* , 2001, The Journal of Biological Chemistry.
[65] H. Abboud,et al. Association and direct activation of signal transducer and activator of transcription1alpha by platelet-derived growth factor receptor. , 1998, The Journal of clinical investigation.
[66] V. Zinzalla,et al. Activation of mTORC2 by Association with the Ribosome , 2011, Cell.
[67] F. Slack,et al. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma , 2010, Nature.
[68] J. Blenis,et al. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways , 2006, Oncogene.
[69] Min Cheol Lee,et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth , 2003, Journal of surgical oncology.
[70] D. Guertin,et al. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.
[71] Mitsuo Kato,et al. MicroRNAs and their role in progressive kidney diseases. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[72] M. Seto,et al. Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c , 2008, The Journal of pathology.
[73] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[74] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[76] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[77] P. Pandolfi,et al. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.
[78] F. Das,et al. PRAS40 acts as a nodal regulator of high glucose‐induced TORC1 activation in glomerular mesangial cell hypertrophy , 2010, Journal of cellular physiology.
[79] Y. Pekarsky,et al. Reprogramming of miRNA networks in cancer and leukemia. , 2010, Genome research.
[80] Tak W. Mak,et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.
[81] Masafumi Ohtsubo,et al. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells , 2001, Oncogene.
[82] Guoku Hu,et al. Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells , 2010, Nucleic acids research.
[83] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[84] Hyung-Seok Kim,et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. , 2003 .
[85] Masafumi Ohtsubo,et al. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. , 2003, Carcinogenesis.
[86] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[87] Peter Bühlmann,et al. Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer , 2009, Clinical Cancer Research.
[88] John E. Burke,et al. Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases , 2011, Science Signaling.
[89] I. Gout,et al. The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.
[90] R. Loewith,et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.
[91] Jacquelyne S Poon,et al. Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway , 2010, Cell cycle.
[92] Ming Zhou,et al. Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma , 2011, Genes, chromosomes & cancer.
[93] L. Mahimainathan,et al. Inactivation of Platelet-derived Growth Factor Receptor by the Tumor Suppressor PTEN Provides a Novel Mechanism of Action of the Phosphatase* , 2004, Journal of Biological Chemistry.
[94] C. Taylor,et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. , 2006, Cancer research.
[95] D. Riley,et al. Raptor-rictor axis in TGFβ-induced protein synthesis , 2008 .
[96] D. Riley,et al. Raptor-rictor axis in TGFbeta-induced protein synthesis. , 2008, Cellular signalling.
[97] Shamit Soneji,et al. Microrna expression distinguishes between germinal center B cell‐like and activated B cell‐like subtypes of diffuse large B cell lymphoma , 2007, International journal of cancer.
[98] R. Parsons,et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. , 2008, Cancer research.
[99] Yurong Fu,et al. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues , 2010, Journal of Cancer Research and Clinical Oncology.
[100] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[101] M. Doucet,et al. Renal cell carcinoma bone metastasis—elucidating the molecular targets , 2007, Cancer and Metastasis Reviews.
[102] J. Downward,et al. Protein Kinase B Activation and Lamellipodium Formation Are Independent Phosphoinositide 3-Kinase-Mediated Events Differentially Regulated by Endogenous Ras , 1998, Molecular and Cellular Biology.
[103] P. Dennis,et al. PTEN loss in the continuum of common cancers, rare syndromes and mouse models , 2011, Nature Reviews Cancer.
[104] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[105] O. Rouvière,et al. Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? , 2006, Nature Clinical Practice Oncology.
[106] G. G. Choudhury,et al. Fish oil targets PTEN to regulate NFκB for downregulation of anti-apoptotic genes in breast tumor growth , 2009, Breast Cancer Research and Treatment.
[107] L. Cantley,et al. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[108] Amy E Pasquinelli. Paring MiRNAs Through Pairing , 2010, Science.
[109] F. Waldman,et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.
[110] K. Kosik,et al. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.
[111] S. Lowe,et al. A microRNA polycistron as a potential human oncogene , 2005, Nature.
[112] Pier Paolo Pandolfi,et al. Tenets of PTEN Tumor Suppression , 2008, Cell.
[113] A. Novick. Kidney cancer: past, present, and future. , 2007, Urologic oncology.
[114] E. Lai,et al. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. , 2011, Molecular cell.
[115] W. Filipowicz,et al. Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.
[116] Alice Shapiro,et al. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. , 2008, Cancer research.
[117] Kenneth M. Yamada,et al. Tumor Suppressor PTEN Inhibits Integrin- and Growth Factor–mediated Mitogen-activated Protein (MAP) Kinase Signaling Pathways , 1998, The Journal of cell biology.
[118] George A Calin,et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.
[119] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[120] W. Kaelin,et al. Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.